Examining the Relationship Between Pre- and Postprandial Glucose Levels and Insulin Bolus Timing Using Bluetooth-Enabled Insulin Pen Cap Technology and Continuous Glucose Monitoring
Abstract
Background: Timing of insulin administration in persons using multiple daily injections (MDI) is self-reported. New technology enabling tracking and logging of insulin doses, combined with continuous glucose monitoring (CGM), may provide insight into the relationship between insulin administration and glucose levels. Methods: We performed a prospective observational study using Bluetooth-enabled pen caps, along with CGM, in participants with type 1 diabetes (T1D) on MDI to objectively assess the relationship between the timing of insulin administration and its impact on pre- and postprandial glucose levels for a 2-week period. Results: We evaluated 50 participants (age 40.3 ± 19 years; A1c 8.2% ± 1.5%, duration of T1D 20 ± 15 years). Thirty-seven percent of total boluses resulted in persistent hyperglycemia (glucose >180 mg/dL 3 h postprandially), while 10% resulted in clinically significant hypoglycemia (glucose <55 mg/dL 3 h postprandially) on CGM. Preprandial glucose levels at the time of the bolus did not correlate with postprandial glucose levels. Late boluses, defined as a rise in glucose of ≥50 mg/dL before a bolus, were seen two times/patient/week. Missed boluses, defined as a rise in glucose of ≥50 mg/dL without a bolus within 2 h, occurred 17 times/patient/week. Late and missed boluses were associated with worse glycemic control (A1c; R 2 = 0.1, P = 0.02; R 2 = 0.1, P = 0.02). Conclusions: The use of Bluetooth-enabled pen caps, with CGM, in persons with T1D on MDI can illustrate the relationship between insulin bolus timing and postprandial glucose. These data may help clinicians and patients understand the impact of timing of insulin doses on glucose levels and glycemic control.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In an observational study of 50 participants with T1D on multiple daily injection therapy using a Bluetooth-enabled pen cap and continuous glucose monitoring, 37% of total boluses resulted in persistent 3-hour postprandial hyperglycemia, while 10% resulted in clinically significant 3-hour postprandial hypoglycemia (glucose <55 mg/dL).
“In an observational study of 50 participants with T1D on MDI therapy using a Bluetooth-enabled pen cap and CGM, it was noted that 37% of total boluses resulted in persistent 3-h postprandial hyperglycemia, while 10% resulted in clinically significant 3-h postprandial hypoglycemia (glucose <55 mg/dL).18”
From Shining the Spotlight on Multiple Daily Insulin Therapy: Real-World Evidence of the InPen Smart Insulin Pen (2024) · cites this paper as [18]
Research from individuals using multiple daily injection therapy with continuous glucose monitoring and connected insulin pen or cap devices revealed that missed, mistimed, and mismatched insulin bolus doses are common and occur in both older and younger populations with T1D or T2D, and are associated with higher A1C.
“Research from individuals using MDI therapy with CGM and connected insulin pen or cap devices revealed that missed, mistimed, and mismatched insulin bolus doses are common and occur in both older and younger populations with T1D or T2D, and are associated with higher A1C.13–18”
From Shining the Spotlight on Multiple Daily Insulin Therapy: Real-World Evidence of the InPen Smart Insulin Pen (2024) · cites this paper as [18]
The citation lists haven’t been fetched yet
References 16 · Cited by 39
- Authors
- Toschi, E., Slyne, C., Greenberg, J. M., Greaves, T., Atakov-Castillo, A., Carl, S., Dufour, A. B., & Munshi, M.
- Affiliations
- Joslin Diabetes Center (US)
- Harvard University (US)
- Corresponding author
- Toschi, Elena
- ORCID
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 22
- Issue
- 1
- Pages
- 19-24
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2971713860
- Cited by
- 39
- References
- 16
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 4
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Technology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, multiple daily insulin injections, continuous glucose monitoring, postprandial blood glucose, preprandial glucose, glycemic control, hypoglycemia, hyperglycemia
- MeSH terms
- Wearable Electronic Devices, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Prospective Studies, Postprandial Period, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review